• Japanese
  • Korean
  • Chinese
Cover Image

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn't cause major disruption to domestic blood products market, the total plasma volume in China blood products industry reduced by 2.8% year on year and total lot release volume declined by 7% from a year earlier in 2013, due to stock consumption, insufficient utilization of new plasma stations and production break of some companies (e.g. Guizhou Taibang Biological Products Co., Ltd and Guangdong Wellen Biological Pharmaceutical Co., Ltd. on account of upgrading and reconstruction, Shanghai RAAS Blood Products Co., Ltd. affected by floods).

However, some niche varieties of blood products, such as scarce human coagulation factor VIII, maintained higher growth in lot release volume. In 2013, the human coagulation factor VIII produced by Shandong Taibang and CNBG Shanghai Institute of Biological Products were approved for release and came into the market, making the lot release volume of the product during the same period amount to 526,000 bottles, soaring by 44.5% on year-on-year basis.

Because of robust demand from China blood products market, the total lot release volume of imported human albumin reached 14.39 million bottles (about 10g/bottle) in 2013, a year-on-year increase of 24.1%, accounting for 53.4% (45.3% in 2012) of the total lot release volume of human albumin during the same period. Assuming absolute superiority, Behring, Baxter, Grifols and Octapharma still held the ground as the top four exporters of human albumin to China.

Despite a slight year-on-year decline in output and sales volume, major Chinese blood products companies, by and large, maintained steady revenue growth in 2013, thanks to rising prices of blood products (the highest retail prices of fibrinogen and blood coagulation factor VIII rose over 50% year on year). China Biologic Products, Hualan Bio, Tiantan Biological Products, Shanghai RAAS and Yuanda Shuyang Pharmaceutical, which hold combined 60% of the total plasma volume, generated total revenue of about RMB4.2 billion in 2013, up 13.5% year on year. Among them, Shanghai RAAS, due to production halt caused by flood, earned only RMB496 million, down 25.1% year on year.

? Attracted by national policy support and high market prosperity, qualified Chinese blood products companies are actively engaged in construction of new plasma stations, some of which are expected to collect plasma by the end of 2014. In June 2014, Wuhan Zhongyuan Ruide Biological Product Co., Ltd. (100% controlled by Humanwell Healthcare (Group) Co., Ltd.)'s plasmapheresis center in Chibi was approved to collect plasma; In May 2014, Hualan Bio's plasma station in Hua County, Henan Province was approved to be set up; In April 2014, Hebei Da'an Pharmaceutical (90% stake controlled by Walvax Biotechnology Co., Ltd.) carried out on-site GMP compliance certification for its plasma station in Wei County; At the end of 2013, Guangdong Shuanglin Bio-pharmacy's plasma stations in Xi County and Jiang County of Shanxi were completed.

In addition, as the Ministry of Health stipulates that the blood products production units with registered varieties of blood products less than 6, and the blood products production units, which undertake national planned immunization task, with registered varieties of blood products less than 5, shall not apply to set up new plasmapheresis centers. Therefore, some superior blood products companies are improving their competitiveness by acquiring small ones which have single product mix but plasma stations. In June 2013, Jiangxi Boya Bio-pharmaceutical Co., Ltd. acquired 32% stake in Zhejiang Haikang Biological Products Co., Ltd., which had two plasma stations and held 41.98% stake in Xinjiang Deyuan Bioengineering Co., Ltd., which possessed 6 plasma stations. In March 2013, Shanghai RAAS set about purchasing Zhengzhou Banghe Pharmaceutical (now known as Zhengzhou RAAS) with RMB1.8 billion, with capital settlement completed in January 2014.

image1

China Blood Products Industry Report, 2014-2017 focuses on the following:

  • Market size, plasma volume, distribution of plasma stations, supply and demand, import and export, etc. of China blood products industry;
  • Competitive landscape, policy environment, development forecast, etc. of China blood products industry;
  • Supply and demand, competitive landscape, etc. of 8 blood product segments, including human albumin, Human Immunoglobulin (pH4) for Intravenous Injection, blood coagulation factor and human rabies immunoglobulin (HRIG).
  • Operation, blood products business and development prospects of 12 major Chinese blood products companies.

Table of Contents

1. Overview of Blood Product Industry

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 Recombinant Blood Products
  • 1.4 Industry Chain
  • 1.5 Features

2. Overview of China Blood Product Industry

  • 2.1 Market Size
  • 2.2 Development
  • 2.3 Supply & Demand
    • 2.3.1 Supply
    • 2.3.2 Demand
  • 2.4 Competition
  • 2.5 Operating Environment
    • 2.5.1 International Market
    • 2.5.2 Policy Environment
    • 2.5.3 Domestic Biopharmaceutical Market
  • 2.6 Import & Export

3. Blood Product Market Segments in China

  • 3.1 Human Albumin
    • 3.1.1 Supply & Demand
    • 3.1.2 Competitive Landscape
    • 3.1.3 Development Prospects
  • 3.2 Human Immunoglobulin (pH4) for Intravenous Injection
    • 3.2.1 Supply & Demand
    • 3.2.2 Competitive Landscape
  • 3.3 Blood Coagulation Factor VIII
    • 3.3.1 Supply & Demand
    • 3.3.2 Competitive Landscape
    • 3.3.3 Development Prospects
  • 3.4 Hepatitis B Immunoglobulin
    • 3.4.1 Supply & Demand
    • 3.4.2 Competitive Landscape
  • 3.5 Human Immunoglobulin
    • 3.5.1 Supply & Demand
    • 3.5.2 Competitive Landscape
  • 3.6 Human Prothrombin Complex
    • 3.6.1 Supply & Demand
    • 3.6.2 Competitive Landscape
  • 3.7 Tetanus Immunoglobulin
    • 3.7.1 Supply & Demand
    • 3.7.2 Competitive Landscape
  • 3.8 Human Rabies Immunoglobulin
    • 3.8.1 Supply & Demand
    • 3.8.2 Competitive Landscape

4. Major Chinese Manufacturers

  • 4.1 China Biologic Products Inc.
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Customers and Suppliers
    • 4.1.5 R&D and Investment
    • 4.1.6 Shandong Taibang Biological Products Co., Ltd.
    • 4.1.7 Guizhou Taibang Biological Products Co., Ltd.
    • 4.1.8 Xi'an Huitian Blood Products Co., Ltd.
    • 4.1.9 Outlook and Prediction
  • 4.2 Hualan Biological Engineering Inc.
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 Customers and Suppliers
    • 4.2.6 R&D and Investment
    • 4.2.7 Blood Products
    • 4.2.8 Outlook and Prediction
  • 4.3 Shanghai RAAS Blood Products Co., Ltd.
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 Customers and Suppliers
    • 4.3.6 R&D and Investment
    • 4.3.7 Outlook and Prediction
  • 4.4 Beijing Tiantan Biological Products Co., Ltd.
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 Customers and Suppliers
    • 4.4.6 R&D and Investment
    • 4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)
    • 4.4.8 Outlook and Prediction
  • 4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd.
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 Customers and Suppliers
    • 4.5.6 R&D and Investment
    • 4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
    • 4.5.8 Outlook and Prediction
  • 4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd.
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 Customers and Suppliers
    • 4.6.6 R&D and Investment
    • 4.6.7 Outlook and Prediction
  • 4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
    • 4.7.1 Profile
    • 4.7.2 Blood Products
  • 4.8 Shanghai Institute of Biological Products Co., Ltd.
    • 4.8.1 Profile
    • 4.8.2 Blood Products
  • 4.9 Shanxi Kangbao Biological Product Co., Ltd.
    • 4.9.1 Profile
    • 4.9.2 Blood Products
  • 4.10 Green Cross
    • 4.10.1 Profile
    • 4.10.2 Blood Products
  • 4.11 Humanwell Healthcare Group Co., Ltd.
    • 4.11.1 Profile
    • 4.11.2 Operation
    • 4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
  • 4.12 Walvax Biotechnology Co, Ltd.
    • 4.12.1 Profile
    • 4.12.2 Operation
    • 4.12.3 Blood Products (Hebei Da'an Pharmaceutical Co., Ltd.)

5. Summary and Forecast

  • 5.1 Company Analysis
  • 5.2 Forecast

Selected Charts

  • Basic Components of Blood
  • Classification and Efficacy of Blood Products
  • Comparison between Gene Recombinant Blood Products and Traditional Blood Products
  • Comparison between Gene Recombinant Blood Products and Traditional Blood Products in China and Overseas
  • Blood Product Industry Chain
  • Prices of Some Blood Products in China, 2013
  • Market Size of Blood Products in China, 2003-2013
  • Lot Release Volume of Blood Products (by Product) in China, 2008-2013
  • Product Structure of Blood Products in China (by Lot Release Volume), 2009-2013
  • Annual Plasma Volume in China, 2002-2013
  • Geographical Distribution of Plasma Collection Stations in China as of June 2014
  • Main Blood Products with Medical Insurance Coverage in China
  • Comparison of Per Capita Usage of Blood Products in China and Developed Countries
  • Plasma Station Distribution, Plasma Volume and Blood Product Revenue of Major Blood Product Manufacturers in China, 2013
  • Product Structure of Global Blood Products
  • Blood Products on Sale in Foreign Countries
  • On-going Clinical Trial of New Indications Overseas
  • Global Blood Product Manufacturers
  • Major Policies on Blood Products in China
  • Price of Human Albumin in China, 2003-2012
  • Ratio of Domestically-produced to Imported Human Albumin in China (by Lot Release Volume), 2007-2013
  • Market Share of Major Human Albumin Manufacturers in China (by Lot Release Volume), 2008-2013
  • Comparison between Consumption of Human Immunoglobulin (pH4) for Intravenous Injection in China and the United States, 2010
  • Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2013
  • Prices of Human Immunoglobulin (pH4) for Intravenous Injection in China and Other Countries
  • Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2013
  • Lot Release Volume and Growth Rate of Blood Coagulation Factor VIII in China, 2008-2013
  • Market Share of Major Blood Coagulation Factor VIII Manufacturers in China (by Lot Release Volume), 2008-2013
  • Comparison between Human Blood Coagulation Factor VIII and Recombinant Blood Coagulation Factor VIII
  • Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2009-2013
  • Market Share of Major Hepatitis B Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2013
  • Prices of Human Immunoglobulin in China by Dosage, 2013
  • Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2013
  • Market Share of Major Human Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2013
  • Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2008-2013
  • Market Share of Major Human Prothrombin Complex Manufacturers in China (by Lot Release Volume), 2008-2013
  • Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2012
  • Market Share of Major Tetanus Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2013
  • Lot Release Volume and Growth Rate of Human Rabies Immunoglobulin in China, 2008-2013
  • Market Share of Major Human Rabies Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2013
  • Equity Structure of China Biologic Products by the End of 2013
  • Revenue and Operating Income of China Biologic Products, 2007-2014
  • Gross Margin of China Biologic Products, 2011-2013
  • Revenue Breakdown of China Biologic Products by Product, 2011-2013
  • Revenue Structure of China Biologic Products by Product, 2010-2012
  • China Biologic Products' Revenue from Top 5 Customers and % of Total Revenue, 2008-2013
  • R&D Costs and % of Total Revenue of China Biologic Products, 2010-2013
  • New Products of China Biologic Products under Research by the End of 2013
  • Lot Release Volume of Blood Products of Shandong Taibang, 2008-2013
  • Lot Release Volume of Blood Products of Guiyang Qianfeng, 2008-2013
  • Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2008-2013
  • Revenue and Operating Income of China Biologic Products, 2012-2017E
  • Revenue and Operating Income of Hualan Biological, 2007-2013
  • Revenue Breakdown of Hualan Biological by Sector, 2007-2013
  • Revenue Breakdown of Hualan Biological by Product, 2007-2013
  • Gross Margin of Hualan Biological by Product, 2007-2012
  • Hualan Biological's Revenue from Top 5 Customers and % of Total Revenue, 2007-2013
  • Hualan Biological' Procurement from Top Five Suppliers and % of Total Procurement, 2007-2012
  • R&D Costs and % of Total Revenue of Hualan Biological, 2007-2013
  • Varieties and Specifications of Blood Products of Hualan Biological
  • Plasma Collection Station Distribution of Hualan Biological by May 2014
  • Lot Release Volume of Blood Products of Hualan Biological, 2008-2012
  • Revenue from and Gross Margin of Blood Products of Hualan Biological, 2007-2013
  • Revenue and Gross Margin of Hualan Biological by Product, 2007-2013
  • Revenue and Operating Income of Hualan Biological, 2012-2017E
  • Distribution of Plasma Collection Stations of Shanghai RAAS by the End of 2013
  • Revenue and Operating Income of Shanghai RAAS, 2008-2014
  • Lot Release Volume of Shanghai RAAS's Blood Products, 2008-2013
  • Operating Revenue Breakdown of Shanghai RAAS by Product, 2008-2013
  • Revenue Breakdown of Shanghai RAAS by Region, 2007-2013
  • Gross Margin of Shanghai RAAS by Product, 2007-2013
  • Shanghai RAAS's Revenue from Top 5 Customers and % of Total Revenue, 2007-2013
  • Shanghai RAAS's Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2012
  • R&D Costs and % of Total Revenue of Shanghai RAAS, 2007-2013
  • Revenue and Operating Income of Shanghai RAAS, 2012-2017E
  • Major Shareholding Companies of Tiantan Biological and Their Revenue, Net Income, 2013
  • Revenue and Operating Income of Tiantan Biological, 2007-2014
  • Revenue Breakdown of Tiantan Biological by Sector, 2007-2013
  • Revenue Breakdown of Tiantan Biological by Region, 2007-2013
  • Gross Margin of Tiantan Biological by Sector, 2007-2013
  • Tiantan Biological's Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2013
  • Tiantan Biological's Revenue from Top 5 Customers and % of Total Revenue, 2007-2013
  • Name List and Revenue Contribution of Tiantan Biological's Top 5 Customers, 2013
  • R&D Costs and % of Total Revenue of Tiantan Biological, 2009-2013
  • Distribution of Blood Plasma Collection Stations of Tiantan Biological by the End of 2013
  • Revenue from and Gross Margin of Blood Products Business of Tiantan Biological, 2007-2012
  • Lot Release Volume of Blood Products of Tiantan Biological, 2008-2013
  • Revenue and Operating Income of Tiantan Biological, 2012-2017E
  • Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2008-2014
  • Operating Revenue Breakdown of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2013
  • Gross Margin of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2013
  • Zhenxing Biopharmaceutical and Chemical's Revenue from Top 5 Customers and % of Total Revenue, 2009-2013
  • Zhenxing Biopharmaceutical and Chemical's Procurement from Top 5 Suppliers and % of Total Procurement, 2013
  • R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical and Chemical, 2009-2013
  • Progress of Products under Research of Zhenxing Biopharmaceutical and Chemical by the end of 2013
  • Plasma Volume of Shuanglin Bio-Pharmacy, 2010-2013
  • Distribution of Plasma Collection Stations of Shuanglin Bio-Pharmacy by the End of 2013
  • Lot Release Volume of Blood Products of Shuanglin Bio-Pharmacy, 2008-2013
  • Revenue from and Gross Margin of Blood Products Business of Zhenxing Biopharmaceutical and Chemical, 2009-2013
  • Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2012-2017E
  • Plasma Collection Volume of Jiangxi Boya Bio-Pharmaceutical, 2008-2013
  • Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2008-2014
  • Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2013
  • Lot Release Volume of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2011-2013
  • Operating Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical by Region, 2009-2013
  • Gross Margin of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2012
  • Jiangxi Boya Bio-Pharmaceutical's Revenue from Top 5 Customers and % of Total Revenue, 2009-2013
  • Name List and Revenue Contribution of Jiangxi Boya Bio-Pharmaceutical's Top 5 Customers, 2013
  • Jiangxi Boya Bio-Pharmaceutical's Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2012
  • R&D Costs and % of Total Revenue of Jiangxi Boya Bio-Pharmaceutical, 2009-2013
  • Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2012-2017E
  • Distribution of Blood Plasma Collection Stations of Yuanda Shuyang by the End of 2013
  • Lot Release Volume of Blood Products of Yuanda Shuyang, 2008-2013
  • Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2008-2013
  • Distribution of Blood Plasma Collection Stations of CNBG Shanghai Institute of Biological Products by the End of 2012
  • Distribution of Blood Plasma Collection Stations of Shanxi Kangbao Biological Product by the End of 2013
  • Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2013
  • Distribution of Blood Plasma Collection Stations of Green Cross China by the End of 2013
  • Lot Release Volume of Blood Products of Green Cross China, 2008-2013
  • Revenue and Operating Income of Humanwell Healthcare (Group), 2009-2013
  • Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Product, 2008-2013
  • Production Industry Layout of Walvax Biotechnology
  • Revenue and Operating Income of Walvax Biotechnology, 2009-2014
  • Revenue Breakdown of Walvax Biotechnology by Sector, 2009-2013
  • Distribution of Plasma Stations of Major Blood Products Manufacturers in China by June 2014
  • Plasma Volume of Major Blood Products Manufacturers in China, 2013
  • Revenue from Blood Products of Major Blood Products Manufacturers in China, 2011-2013
  • Production Lines Comparison of Blood Products Manufacturers in China
  • China Blood Products Market Size, 2012-2017E
  • Gross Margin of Major Blood Products Manufacturers in China, 2011-2013

Related Companies

  • Hualan Biological Engineering Inc.(002007.SZ)
  • Shanghai RAAS Blood Products Co.,Ltd.(002252.SZ)
  • Beijing Tiantan Biological Products Corporation Limited(600161.SH)
  • Zhenxing Biopharmaceutical and Chemical Co., Ltd.(000403.SZ)
  • Jiangxi Boya Bio-Pharmaceutical Co., Ltd(300294.SZ)
  • Wuhan Humanwell Healthcare (Group) Co.,Ltd(600079.SH)
  • Walvax Biotechnology Co.,Ltd.(300142.SZ)
Show More
Pricing